Aktienanalyse zu Skye Bioscience Inc (SKYE)SKYESkye Bioscience Inc

Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $0.9925 and the RSI of 13.72 indicating extreme oversold conditions, the stock is not a good buy right now. The company has reported significant losses, with a net income of -$12,509,361 in Q1 2026, and a forward P/E ratio of 0, suggesting no earnings growth is expected in the near term. The major risk is the high volatility and the potential for further declines, as indicated by a 5-day change of -22.46%.